Navigation Links
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Date:11/3/2011

THE WOODLANDS, Texas, Nov. 3, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. David Powell, senior vice president of metabolism research, will present data from clinical and preclinical studies of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), at the Cambridge Healthtech Institute's Diabetes Drug Discovery conference in Boston, Massachusetts on Friday, November 4, 2011.

In clinical studies to date, LX4211 has demonstrated a favorable safety profile and beneficial effects on multiple parameters of glycemic control and cardiovascular health.  Recent studies in healthy subjects have shown that LX4211 substantially decreases postprandial glucose levels without hypoglycemia and substantially reduces triglycerides, results that have not been reported for SGLT2-selective inhibitors.  Data from a mechanistic study in patients with type 2 diabetes demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  In addition, postprandial release of GLP-1 and PYY from the gastrointestinal (GI) tract has been observed in preclinical studies of SGLT1 knockout mice but not in SGLT2 knockout mice, indicating that inhibition of SGLT1 function may trigger the postprandial release of these important regulators of glycemic and appetite control.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211.  This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... The global  parenteral nutrition ... by 2024, according to a new report by ... the growing malnutrition coupled with the prevalence of ... diseases are expected to boost the market over ... http://photos.prnewswire.com/prnh/20150105/723757 ) , The presence ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for treating ... becomes 5th off-the-shelf Stem cell product to be approved by a ... (also known as Thromboangiitis Obliterans) is a major unmet medical need ... Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... European Community & USA Stempeutics ...
(Date:5/30/2016)... 2016 Eye expert s ... to seek an eye examination before ...   Moorfields Eye Hospital Dubai, the first overseas ... , has identified premature babies as a special concern in ... particular vulnerability to retinopathy of prematurity (ROP). ROP is a potentially ...
Breaking Medicine Technology:
(Date:5/31/2016)... Atlanta, GA (PRWEB) , ... May 31, 2016 ... ... avoidable readmissions using a mix of advanced Artificial Intelligence (AI) and the latest ... predictive solution. The medical center is integrating predictive analytic outputs directly into the ...
(Date:5/31/2016)... MN (PRWEB) , ... May 31, 2016 , ... DDL, ... the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO 594-2 ... common means of achieving a leak-free connection between two medical devices (e.g. a syringe ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spartan Bioscience ... enables unprecedented portability and convenience. , The Cube is exceptionally small—it takes up ... the Cube fits easily into any space, whether in a hospital, doctor’s office, ...
(Date:5/31/2016)... ... May 31, 2016 , ... The successful implementation of ... their laboratories as well. However, laboratories have different challenges compared to manufacturing environments. ... operations in the lab, METTLER TOLEDO has developed the Lean Lab Checklist . ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Global Wellness ... released ten predictions on the future of wellness, travel, spa and beauty in Europe. ... spa and beauty companies to leading economists and researchers - to forecast where wellness ...
Breaking Medicine News(10 mins):